Piper Sandler analyst Jason Bednar downgraded Koru Medical (KRMD) to Neutral from Overweight with an unchanged price target of $4.50. The company’s execution “has unquestionably improved,” but the stock’s valuation is sitting near multi-year highs even off potentially higher revenue numbers, the analyst tells investors in a research note. The firm says Koru’s “loftier valuation” is making it “slightly more uneasy about other items,” including tougher compares for the U.S. subcutaneous immunoglobulin market, its limited gross margin upside in 2025 and 2026 due to geographic mix, and novel therapies revenue catalysts that look more weighted to 2026 and beyond. As such, Piper believes other stocks offer a superior risk/reward.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD:
- Koru announces pact for next-gen subcutaneous immunoglobulin infusion system
- Koru Medical announces Phase 3 trial collaboration for new drug indication
- Koru Medical price target raised to $6 from $5 at Craig-Hallum
- Koru Medical price target raised to $5 from $4 at Lake Street
- REPRO-MED Systems Releases Investor Presentation Online